Estimation of Apelin and Fibroblast growth factor-21 (FGF-21) in periodontal disease and Diabetes patients
Not Applicable
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2024/07/070058
- Lead Sponsor
- Dr Swathi S Kumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients who have not received any periodontal treatment in previous six months.
2. Patients diagnosed with T2DM as per
American Diabetes Association criteria (2019).
3. Patients with a diagnosis of Generalized Periodontitis as per World Workshop Classification criteria (2017).
Exclusion Criteria
1. Smokers and alcoholics.
2. Patients with systemic diseases like hypertension, cardiovascular
diseases, rheumatoid arthritis, tumours, autoimmune diseases and
renal diseases.
3. Pregnant, lactating females and post menopausal women.
4. Any other systemic disease which can alter the course of
periodontal disease.
5. Patients on any medication like anti-inflammatory drugs,
antibiotics and anti-epileptic drugs in the past 6 months.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparatively evaluate salivary and serum levels of Apelin and FGF-21 in periodontitis and T2DM patients. <br/ ><br>Explore any correlation of Apelin with FGF-21 and clinical parameters.Timepoint: Baseline
- Secondary Outcome Measures
Name Time Method Explore any correlation of Apelin with FGF-21 and clinical, biochemical & demographic parameters.Timepoint: Baseline